LTRN (Lantern Pharma) Net Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTRN Lantern Pharma Inc LTRN
33 GF Score
Price $2.98
! 2 Warning Signs
View Full Analysis

What is Lantern Pharma Net Margin %?

Lantern Pharma LTRN -0.34% 33 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates LTRN with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 942 Biotechnology companies, Lantern Pharma ranks worse than 106157.01% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Lantern Pharma's Net Income for the three months ended in Mar. 2026 was $-3.33 Mil. Lantern Pharma's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Lantern Pharma's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Lantern Pharma's Net Margin % or its related term are showing as below:


LTRN's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.295
* Ranked among companies with meaningful Net Margin % only.

Lantern Pharma  (NAS:LTRN) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Lantern Pharma Net Margin % Related Terms

Lantern Pharma Net Margin % Historical Data

* Premium members only.

The historical data trend for Lantern Pharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lantern Pharma Net Margin % Chart

Lantern Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Lantern Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LTRN vs PDSB, AURX, TIL: Net Margin % Comparison

For the Biotechnology subindustry, Lantern Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lantern Pharma Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lantern Pharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where Lantern Pharma's Net Margin % falls into.


LTRN
33GF Score
Lantern Pharma Inc LTRN
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lantern Pharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Lantern Pharma's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-17.119/0
= %

Lantern Pharma's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-3.329/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Lantern Pharma (LTRN) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Lantern Pharma and its competitors. According to the industry distribution chart, Lantern Pharma ranks #999999 out of 942 companies in the Biotechnology industry.
Is Lantern Pharma's Net Margin % too high?
Lantern Pharma's current Net Margin % is 0.00%. Based on the distribution chart, Lantern Pharma ranks #999999 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lantern Pharma has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Lantern Pharma's Net Margin % compare to PDSB and AURX?
According to the Biotechnology industry distribution chart, Lantern Pharma ranks #999999 out of 942 companies for Net Margin %. This places Lantern Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Lantern Pharma and its competitors. Lantern Pharma's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantern Pharma stock overvalued right now?
Lantern Pharma (LTRN) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Lantern Pharma's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Lantern Pharma (LTRN), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lantern Pharma Business Description

Address 1920 McKinney Avenue, 7th Floor, Dallas, TX, USA, 75201
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
33GF Score

Get the complete analysis for LTRN

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.98
Price